Status:
NOT_YET_RECRUITING
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Seoul National University Bundang Hospital
Seoul National University Boramae Hospital
Conditions:
Ovarian Cancer
Endometrial Cancer
Eligibility:
FEMALE
19+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer. The main questio...
Detailed Description
Proactive immune tolerance induction is applied using an automated infusion pump with a pre-programmed protocol. It follows the same stepwise dosing scheme as conventional desensitization therapy used...
Eligibility Criteria
Inclusion
- Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies.
- Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin.
- Patients who are able to read and voluntarily provide written informed consent.
- Aged 19 years or older.
Exclusion
- Patients who do not wish to participate in this study voluntarily.
- Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.
Key Trial Info
Start Date :
June 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2028
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06977594
Start Date
June 25 2025
End Date
May 31 2028
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080